EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Low-Dose Ketone Monoester Administration in Adults with Cystic Fibrosis: A Pilot and Feasibility Study

Eric P Plaisance iD, Jonathan M Bergeron iD, Mickey L Bolyard iD, Heather Y Hathorne, Christina M Graziano iD, Anastasia Hartzes, Kristopher R Genschmer iD, Jessica A Alvarez, Amy M Goss iD, Amit Gaggar iD, Kevin R Fontaine

Nutrients · 2024

DOI: 10.3390/nu16223957 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Eric P Plaisance und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Feasibility Studies, Quality of Life, Ketones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, NIH Pilot and Feasibility Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have greatly improved outcomes in persons with CF (pwCF); however, there is still significant heterogeneity in clinical responses, particularly with regard to respiratory infection and inflammation. Exogenous administration of ketones has profound systemic anti-inflammatory effects and produces several nutrient-signaling and metabolic effects that may benefit multiple organ systems affected in pwCF. This pilot study was designed to determine the feasibility of administration of a ketone monoester (KME) to increase circulating D-beta hydroxybutyrate concentrations (D-βHB) and to improve subjective measures of CF-specific quality of life and markers of inflammation in serum and sputum in adults with CF.

Methods

Fourteen participants receiving modulator therapy were randomized to receive either KME (n = 9) or placebo control (PC, n = 5) for 5–7 days during hospitalization for treatment of acute pulmonary exacerbation or as outpatients under standard care.

Results

The KME was well tolerated, with only mild reports of gastrointestinal distress. D-βHB concentrations increased from 0.2 ± 0.1 mM to 1.6 ± 0.6 mM in the KME group compared to 0.2 ± 0.0 to 0.3 ± 0.1 in the PC group (p = 0.011) within 15 min following consumption and remained elevated, relative to baseline, for over 2 h. Pulmonary function was not altered after single- or short-term KME administration, but participants in the KME group self-reported higher subjective respiratory scores compared to PC in both cases (p = 0.031). Plasma inflammatory markers were not statistically different between groups following the short-term (5–7 d) intervention (p > 0.05). However, an exploratory analysis of plasma pre- and post-IL-6 concentrations was significant (p = 0.028) in the KME group but not PC. Sputum IFNγ (p = 0.057), IL-12p70 (p = 0.057), IL-1β (p = 0.100), IL-15 (p = 0.057), IL-1α (p = 0.114), and MPO (p = 0.133) were lower in the KME group compared to PC but did not achieve statistical significance.

Conclusions

With the emerging role of exogenous ketones as nutrient signaling molecules and mediators of metabolism, we showed that KME is well tolerated, increases circulating D-βHB concentrations, and produces outcomes that justify the need for large-scale clinical trials to investigate the role of KME on whole-body and tissue lipid accumulation and inflammation in pwCF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisFeasibility StudiesQuality of LifeKetonesHumansPilot ProjectsAdultMaleFemaleYoung AdultSputumCystic Fibrosis Transmembrane Conductance Regulator3-Hydroxybutyric AcidBiomarkersEstersInflammationAnti-Inflammatory AgentsDouble-Blind Method

Stichwörter der Autor:innen

inflammationketogenic dietketoneslow-carbohydrate dietpulmonary function

Substanzen

KetonesCystic Fibrosis Transmembrane Conductance Regulator3-Hydroxybutyric AcidBiomarkersEstersAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Division of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Department of Health & Kinesiology, University of Utah, Salt Lake City, UT 84112, USA.
  • Department of Human Studies, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University, Atlanta, GA 30322, USA.

ORCID-Profile: Eric P Plaisance, Jonathan M Bergeron, Mickey L Bolyard, Christina M Graziano, Kristopher R Genschmer, Amy M Goss, Amit Gaggar

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • NIH Pilot and Feasibility Award

Zitieren

APA

Plaisance, E. P., Bergeron, J. M., Bolyard, M. L., Hathorne, H. Y., Graziano, C. M., Hartzes, A., Genschmer, K. R., Alvarez, J. A., Goss, A. M., Gaggar, A., & Fontaine, K. R. (2024). Low-Dose Ketone Monoester Administration in Adults with Cystic Fibrosis: A Pilot and Feasibility Study. Nutrients. https://doi.org/10.3390/nu16223957

Vancouver

Plaisance EP, Bergeron JM, Bolyard ML, Hathorne HY, Graziano CM, Hartzes A, et al. Low-Dose Ketone Monoester Administration in Adults with Cystic Fibrosis: A Pilot and Feasibility Study. Nutrients. 2024. doi:10.3390/nu16223957

BibTeX
@article{Plaisance2024,
  author = {Plaisance, Eric P and Bergeron, Jonathan M and Bolyard, Mickey L and Hathorne, Heather Y and Graziano, Christina M and Hartzes, Anastasia and Genschmer, Kristopher R and Alvarez, Jessica A and Goss, Amy M and Gaggar, Amit and Fontaine, Kevin R},
  title = {Low-Dose Ketone Monoester Administration in Adults with Cystic Fibrosis: A Pilot and Feasibility Study},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16223957}
}
Kostenlos starten →